000283139 001__ 283139
000283139 005__ 20260106102203.0
000283139 0247_ $$2doi$$a10.1002/dad2.70240
000283139 0247_ $$2pmid$$apmid:41488805
000283139 0247_ $$2pmc$$apmc:PMC12756045
000283139 037__ $$aDZNE-2026-00035
000283139 041__ $$aEnglish
000283139 082__ $$a610
000283139 1001_ $$0P:(DE-2719)9001969$$aKlassen, Paula Cynthia$$b0$$eFirst author$$udzne
000283139 245__ $$aIncreased transmembrane protein 119 (TMEM119) levels in the cerebrospinal fluid of patients with mild cognitive impairment due to Alzheimer's disease suggest early microglial involvement.
000283139 260__ $$aHoboken, NJ$$bWiley$$c2026
000283139 3367_ $$2DRIVER$$aarticle
000283139 3367_ $$2DataCite$$aOutput Types/Journal article
000283139 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767691284_3696
000283139 3367_ $$2BibTeX$$aARTICLE
000283139 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283139 3367_ $$00$$2EndNote$$aJournal Article
000283139 520__ $$aWe aimed to evaluate the potential of the microglial marker transmembrane protein 119 (TMEM119) in the cerebrospinal fluid (CSF) as a (differential) diagnostic biomarker for neurodegenerative diseases.Following assay validation, we used enzyme-linked immunosorbent assay to measure CSF TMEM119 in 174 patients from six diagnostic groups: Alzheimer's disease (AD, n = 35), amyotrophic lateral sclerosis (ALS, n = 33), cerebral microangiopathy (CM, n = 25), frontotemporal lobar degeneration (FTLD, n = 28), Lewy body diseases (n = 21), and non-neurodegenerative controls (n = 33).CSF TMEM119 levels were elevated in the AD group compared to the control (p = 0.004), CM (p = 0.005), and FTLD (p = 0.023) groups. Levels were higher in both mild cognitive impairment (MCI-AD) and dementia (ADD) subgroups when compared to controls. For the discrimination of AD from controls, the area under the curve (AUC) was 0.78.Our results indicate that CSF TMEM119 may have potential as a biomarker representing microglial involvement in early and later stages of AD.Elevated levels of TMEM119 were observed in the CSF of patients with AD.Increased CSF TMEM119 was seen in MCI-AD patients compared to controls.Elevated levels in MCI-AD underscore early microglial involvement in AD.In the AD group, an association was found between CSF TMEM119 and CSF total tau.CSF TMEM119 may provide valuable information on neuroinflammation.
000283139 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283139 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x1
000283139 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283139 650_7 $$2Other$$aAlzheimer's disease
000283139 650_7 $$2Other$$abiomarkers
000283139 650_7 $$2Other$$acerebrospinal fluid
000283139 650_7 $$2Other$$amicroglia
000283139 650_7 $$2Other$$aneuroinflammation
000283139 7001_ $$0P:(DE-2719)9001941$$aAlexudis, Christoforos$$b1$$udzne
000283139 7001_ $$0P:(DE-2719)9001084$$aKlose, Veronika$$b2$$udzne
000283139 7001_ $$ade San José, Nerea Gómez$$b3
000283139 7001_ $$0P:(DE-2719)9002029$$aHuss, André$$b4
000283139 7001_ $$aBachhuber, Franziska$$b5
000283139 7001_ $$aSoylu, Önder$$b6
000283139 7001_ $$aFazeli, Badrieh$$b7
000283139 7001_ $$aErhart, Deborah$$b8
000283139 7001_ $$0P:(DE-2719)9002008$$aLaible, Mona$$b9$$udzne
000283139 7001_ $$aAnderl-Straub, Sarah$$b10
000283139 7001_ $$0P:(DE-2719)9001441$$aJesse, Sarah$$b11$$udzne
000283139 7001_ $$aOtto, Markus$$b12
000283139 7001_ $$0P:(DE-2719)2812633$$aLudolph, Albert$$b13$$udzne
000283139 7001_ $$0P:(DE-2719)9002007$$aTumani, Hayrettin$$b14$$udzne
000283139 7001_ $$0P:(DE-2719)9002026$$aHalbgebauer, Steffen$$b15$$udzne
000283139 773__ $$0PERI:(DE-600)2832898-X$$a10.1002/dad2.70240$$gVol. 18, no. 1, p. e70240$$n1$$pe70240$$tAlzheimer's & dementia / Diagnosis, assessment & disease monitoring$$v18$$x2352-8729$$y2026
000283139 8564_ $$uhttps://pub.dzne.de/record/283139/files/DZNE-2026-00035.pdf$$yRestricted
000283139 8564_ $$uhttps://pub.dzne.de/record/283139/files/DZNE-2026-00035.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283139 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001969$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000283139 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001941$$aExternal Institute$$b1$$kExtern
000283139 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001084$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000283139 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002008$$aExternal Institute$$b9$$kExtern
000283139 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001441$$aExternal Institute$$b11$$kExtern
000283139 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2812633$$aExternal Institute$$b13$$kExtern
000283139 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002007$$aExternal Institute$$b14$$kExtern
000283139 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002026$$aExternal Institute$$b15$$kExtern
000283139 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283139 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x1
000283139 9141_ $$y2026
000283139 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-31$$wger
000283139 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZH DEMENT-DADM : 2022$$d2024-12-31
000283139 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-31
000283139 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-31
000283139 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:09:24Z
000283139 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:09:24Z
000283139 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-08T17:09:24Z
000283139 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-31
000283139 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-31
000283139 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-31
000283139 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALZH DEMENT-DADM : 2022$$d2024-12-31
000283139 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-31
000283139 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-31
000283139 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center (Ulm)$$lClinical Study Center (Ulm)$$x0
000283139 9201_ $$0I:(DE-2719)1910005$$kAG Zhan$$lNeuroepidemiology$$x1
000283139 980__ $$ajournal
000283139 980__ $$aEDITORS
000283139 980__ $$aVDBINPRINT
000283139 980__ $$aI:(DE-2719)5000077
000283139 980__ $$aI:(DE-2719)1910005
000283139 980__ $$aUNRESTRICTED